Home › Funds › Capital Impact Advisors, LLC › KRYS
Capital Impact Advisors, LLC position in KRYS
KRYSTAL BIOTECH INC · Health Care
Capital Impact Advisors, LLC reported holding 80,083 shares of KRYS (KRYSTAL BIOTECH INC) in its Q3 2026 13F filing — a position valued at US$26.6M, representing 2.30% of its reported portfolio and ranking #20 among its reported holdings. Capital Impact Advisors, LLC has disclosed KRYS holdings in 4 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Capital Impact Advisors, LLC's KRYS position evolved
Capital Impact Advisors, LLC first disclosed a stake in KRYS in Q3 2023 at 5,726 shares (US$664K). The position peaked in Q3 2026 at 80,083 shares, worth US$26.6M. Across 4 filings, Capital Impact Advisors, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 80,083 shares valued at US$26.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.73K | $664.22K | New |
| Q4 2023 | 5.73K | $710.37K | Hold |
| Q1 2024 | 5.34K | $950.68K | Reduce |
| Q3 2026 | 80.08K | $26.63M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KRYS and 13F data
KRYS (KRYSTAL BIOTECH INC) is a Health Care company. 42 other funds we track also report a position in KRYS — the largest reported positions include Avoro Capital Advisors LLC (US$1.07B), Soleus Capital Management, L.P. (US$349.1M), Hood River Capital Management LLC (US$246.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KRYS
- Avoro Capital Advisors LLC 2.89M sh · $1.07B · Q2 2026
- Soleus Capital Management, L.P. 939.25K sh · $349.09M · Q2 2026
- Hood River Capital Management LLC 663.38K sh · $246.56M · Q2 2026
- Redmile Group, LLC 632.00K sh · $234.90M · Q2 2026
- Frazier Life Sciences Management, L.P. 481.31K sh · $178.89M · Q2 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 520.92K sh · $173.24M · Q3 2026
- BRAIDWELL LP 128.97K sh · $47.94M · Q2 2026
More on Capital Impact Advisors, LLC
FAQ
How long has Capital Impact Advisors, LLC held KRYS?
Capital Impact Advisors, LLC has disclosed KRYS holdings in 4 of the last 13 reported quarters, going back to Q3 2023.
What is Capital Impact Advisors, LLC's current position in KRYS?
As of Q3 2026, Capital Impact Advisors, LLC holds 80.08K shares of KRYS (KRYSTAL BIOTECH INC), valued at $26.63M, representing 2.30% of its reported portfolio and ranking #20.
Has Capital Impact Advisors, LLC been buying or selling KRYS?
In the latest 13F filing (Q3 2026), Capital Impact Advisors, LLC newly opened its position in KRYS. The position peaked in Q3 2026 at 80.08K shares.
Which other funds hold KRYS?
Other major institutional holders of KRYS include Avoro Capital Advisors LLC, Soleus Capital Management, L.P., Hood River Capital Management LLC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.